Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.
2 reports, 1 independent
Updated Thu 00:00
No new developments lately
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Leerink partners
U.S. investment bank
Related events
- Leerink Partners is acting as a joint book-running manager for an offering by Spyre Therapeutics, Inc.
- Kazia Therapeutics Limited is seeking joint bookrunning management and co-management for a proposed offering, with Leerink partners and Needham & Company involved.
- Leerink Partners started coverage on ANI Pharmaceuticals shares.
- Leerink Partners started coverage on Nautilus Biotechnology on October 6, 2026.
- Leerink Partners provided coverage and price targets for Freenome on September 26, 2026.